Rhianna-lily Smith’s Post

We are entering an era in medicine when new diagnostics can help change the management of #neurodegenerative diseases from “sick care” to #proactive preventative care. In an engaging and open piece about his quest to assess his own risk for dementia, Dr. Sanjay Gupta describes the potential of new, multimodal diagnostic approaches in assessing brain health and providing an action plan to optimizing it through personalized lifestyle changes and therapeutic interventions. While Dr. Gupta’s concerns are shared by most people over 50, his access to many of the types of tests used in his diagnostic journey is not. New technologies are needed to both expand access to personalized assessments of #brain health and provide ways of measuring key #biomarkers of neurodegenerative disease that are not currently measurable.   Amydis, Inc. is the leader in leveraging the #eye as a window to the brain with first-in-class ocular tracers that enable the detection of disease-related biomarkers in the retina. We are in human clinical trials exploring the eye to detect Alzheimer’s disease, Parkinson’s disease, ALS, and other diseases. We envision a future where people can turn to the Amydis #eyetest in their quest to assess their brain health and form an action plan for a healthier future. #Alzheimers #Parkinsons #ALS #patientsfirst CNN https://lnkd.in/ghh9jGSU

What is neurogenesis and neuritogenesis and how might this process impact Alzheimer's disease progression? #Neurogenesis is the production of new neurons and #neuritogenesis is the growth and extension of the branches or neurites of a neuron. Both the neurogenesis and neuritogenesis process slows down or altered as we age and, particularly in patients with dementia. The neurite extension enables neuronal communication, important for healthy memory and cognitive functions. Restoring the neuritogenesis process presents an opportunity to reverse the loss of neuronal function caused by Alzheimer’s disease. INM-901 has demonstrated an ability to extend neurite outgrowth, a promising effect in the treatment of Alzheimer's disease. Learn more: https://ow.ly/x2Ge50Rcikz $INM #Alzheimers #Research #cannabinoids

New in the main journal, Rahimi et al explore neuroimaging changes in patients with mild Wilson disease. Imaging changes can be seen before neuropsychiatric symptoms; myelin or white matter in general seems vulnerable to low-level copper toxicity, with white matter volume loss showing promise as a marker for assessing brain involvement in early WD stages. Brain morphometry in hepatic Wilson disease patients Parya Rahimi, Stanislav Mareček, Radan Brůha, Dezortova Monika, Petr Sojka, Milan Hájek, Marta Skowrońska, Łukasz Smoliński, Petr Urbánek, Tomasz Litwin, Petr Dušek https://lnkd.in/g2NirhAv #wilsondisease #neuroimaging

We all agree that Alzheimer's is a scary disease. With hundreds of billions of dollars invested in ALZ and PD research, we are not getting even close to finding the treatment. The absence of disease-modifying treatments for Alzheimer’s disease has led to the emergence of new pathogenic mechanisms to target - the brain's glymphatic system, the system responsible for the movement of cerebrospinal fluid and clearance of metabolic waste. Glymphatic system should be the main therapeutic focus. Early diagnosis and understanding of core causes are very important. MRI methods for monitoring glymphatic system activity in the CNS can potentially uncover the relationship between glymphatic system activity and pathological alterations. The review “Noninvasive Magnetic Resonance Imaging Measures of Glymphatic System Activity” by Kamagata et al. is a good review of where we stand with noninvasive MRI measures of glymphatic system activity.  Source: https://lnkd.in/gR4PR9RB #EndAlz #AlzheimersDisease #Dementia #MotoGlymphatic

🌟 Exciting News in Alzheimer’s Research! 🌟 Memory clinics across the UK are embarking on a groundbreaking five-year trial involving 5,000 volunteers to revolutionize Alzheimer’s diagnosis. Researchers from University College London and the University of Oxford are leading the charge. 🧠 🔍 The Challenge: Currently, only around 2% of patients undergo the “gold standard” tests—specialist PET brain scans or spinal lumbar punctures—that detect rogue proteins like amyloid and tau in the brain. These proteins accumulate up to 20 years before symptoms emerge. 😮 🌐 The Solution: Enter blood tests! These could offer a cheaper and easier way for doctors to identify early signs of dementia, including Alzheimer’s. Imagine a simple blood draw providing crucial insights into your brain health. 🩸 🔬 Beyond Alzheimer’s: The trial will also explore potential biomarkers for vascular and frontotemporal dementia, as well as dementia with Lewy bodies. A holistic approach to understanding and tackling dementia! 🌈 🤝 Impact: If successful, this initiative could significantly enhance access to care, support, and new drug treatments for those affected by dementia. Let’s champion this research! 💪 #AlzheimersResearch #DementiaAwareness #HealthcareInnovation #BrainHealth #MedicalBreakthroughs

1. Researchers from the Allen Institute and University of Washington Medicine have identified cellular changes in Alzheimer’s disease and a timeline for these changes. 2. The study reveals two main phases of Alzheimer’s: a slow, early phase with low pathology and no cognitive decline, followed by a later phase with significant pathology and cognitive decline. 3. The research involved analyzing millions of cells from 84 deceased Alzheimer’s patients, ranging from mild cases to advanced dementia. 4. The middle temporal gyrus (MTG) was the focus, as it is a critical area where Alzheimer’s evidence appears and worsens. 5. Machine learning technology helped compare Alzheimer’s brain samples to normal brain maps, detecting early cellular changes. 6. The first phase shows a surprising loss of inhibitory neurons, which are crucial for balancing brain activity, marking a critical discovery. 7. The second phase involves extensive neuron loss, leading to the formation of plaques and tangles, which coincide with cognitive decline. 8. The findings suggest that early detection of Alzheimer’s changes could lead to new diagnostics and treatments, emphasizing the importance of studying the "quiet" phase of the disease.

Novel mechanism in brain blood flow regulation offers insights into treating stroke and dementia https://lnkd.in/eXCeWkY3

Novel mechanism in brain blood flow regulation offers insights into treating stroke and dementia https://lnkd.in/eXCeWkY3

Novel mechanism in brain blood flow regulation offers insights into treating stroke and dementia https://lnkd.in/eXCeWkY3

Novel mechanism in brain blood flow regulation offers insights into treating stroke and dementia https://lnkd.in/eXCeWkY3